费诺纤维酸在老鼠脏和肝脏中差异激活PPARα介导的脂质代谢
Venkat R Pannala1,2, Michele R Balik-Meisner3, Deepak Mav3
1Department of Defense Biotechnology High Performance Computing Software Applications Institute, Defense Health Agency Research & Development, Medical Research and Development Command, Fort Detrick, MD, 21702, USA. vpannala@bhsai.org.
费诺纤维酸 (PPARα激动剂) 对肝脏和脏代谢的影响不同,高剂量会导致肝脏损伤. 了解这些PPARα驱动的变化是管理 fenofibrate 的关键.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢学 代谢学 代谢学
- 毒理学 毒理学 毒理学
背景情况:
- 费诺纤维酸,PPARα激动剂,治疗超脂血症,但可能导致肝脏和脏毒性.
- 费诺纤维酸诱导毒性的机制及其对肝脏与脏脂质代谢的差异性影响尚不清楚.
研究的目的:
- 调查费诺纤维酸对大鼠肝脏和脏代谢的剂量依赖性影响.
- 关注PPARα激活和器官特异性毒性机制.
- 分析转录组数据以了解差异化的代谢变化.
主要方法:
- 经过5天的纤维酸暴露后,大鼠肝脏和脏的高通量转录组分析.
- 路径丰富,损伤模块和基因比较分析.
- 对PPARα调节和代谢途径的剂量依赖性评估.
主要成果:
- 费诺纤维酸增加了肝脏体重,并显著改变了肝脏的转录组,而不是脏.
- PPARα和RXRα基因显示肝脏和脏之间的差异调节.
- 识别了脂肪酸,脂蛋白和葡萄糖代谢途径的明显变化,转折点表明从有益作用过渡到有毒作用.
结论:
- 费诺纤维酸对脂质代谢的影响是器官特异性的,由PPARα介导.
- 转录的拐点揭示了纤维酸诱导的肝毒性机制.
- 需要进一步的研究来阐明肝脏和脏中差异性的PPARα信号传递.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
11:03Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes
Published on: September 9, 2021
相关概念视频
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Cell Specific Gene Expression
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
